Vancouver Division of Family Practice and Perinatal Services BC Prenatal Genetic Screening Program Present: Prenatal Genetic Screening Langley Division.

Slides:



Advertisements
Similar presentations
NON – INVASIVE PRENATAL TESTING
Advertisements

Examples of Sound Screening:
Giving Pregnancy Test Results A primer for nursing students.
SOCIAL IMPLICATIONS OF GENETIC PRENATAL SCREENING IN PREGNANCY.
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
Genetic Testing in Pregnancy
Second-trimester maternal serum screening
Prenatal Care Fetal/Maternal Assessment Techniques.
Genetics and Primary Care
Prenatal Testing for Down Syndrome: Where Do We Stand Today? David B. Fox, MD Riverside Methodist Hospital.
Prenatal Genetics OG Supplemental Information Drs. Deborah Driscoll and Michael Mennuti.
The New Prenatal Screening Tests
Non-Invasive Prenatal Testing (NIPT)
Screening for fetal Down’s Syndrome – Improving efficacy and efficiency.
Non-Invasive Prenatal Testing
NON – INVASIVE PRENATAL TESTING
Prenatal Genetic Testing for Chromosomal Anomalies By: Linda DeFranco.
Enhanced Prenatal Screening Program
Best Start - Prenatal Education Program Prenatal Care.
Biochemical tests and ‘marker chemicals’
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
Pregnancy & Newborn Screening Developments
Max Brinsmead MB BS PhD November  Some 1- 2% of babies will have a major disability that dates from the prenatal period  Either  Chromosomal.
New Follow-up Service Introduced by the California Prenatal Screening Program Non-Invasive Prenatal Testing (NIPT, NPT) NIPT: Non-invasive prenatal testing.
Photo: courtesy Travel Alberta.  The provision of information for individuals  Women have the right to access information about the health of their.
First Trimester Screening
Module One: Introduction to the California Prenatal Screening Program
Trifecta for Change: Enhancing Antenatal Care in Ontario TEC Talk May 27 th, 2013 Mari Teitelbaum Michael Pluscauskas, Sandra Dunn, Tracy Carr, Brenda.
SMFM Clinical Practice Guidelines
An Ounce of Prevention  2000, 2005, 2011 The Curators of the University of Missouri Preconception Planning and Monitoring Fetal Health Twenty Questions.
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
In the name of god First Trimester Screening Dr.M.Moradi.
Pregnancy diagnosis, Prenatal care & Genetic counseling Wei Jiang, M.D. Attending of Ob & Gyn Ob & Gyn Hospital, Fudan University 419 Fangxie Road, Shanghai.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
The New Prenatal Screening Tests Langley Memorial Hospital Grand Rounds November 8, 2007 Ken Seethram, MD, FRCSC, FACOG Obstetrics and Gynecology, Burnaby.
The Role of Prenatal screening as part of Routine Obstetric Care
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the ability.
Screening for Down’s syndrome
Non-Invasive Prenatal Testing (NIPT)
Module Five: Viewing Results in SIS. Introduction – Viewing Results Accurately communicating case interpretation to patients is one of the most important.
Prenatal Screening By Karissa Parsons and Melissa Fakunle.
Erika Castro, PGY 3 Cook County-Loyola-Provident Family Medicine Residency 2/27/2014 PRENATAL SCREENING AND DIAGNOSIS COUNSELING
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
Non-invasive Prenatal Testing
Fetal Diagnosis & Counseling of Pregnancy Options.
1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.
UOG Journal Club: January 2016 Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results.
UOG Journal Club: July 2013 Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies M. M. Gil, M. S. Quezada, B. Bregant,
Prenatal Screening and Diagnosis. What is Prenatal Diagnosis?  In-utero detection of fetal anomalies General population risk is 3-5% for any birth defect.
a systematic review and meta-analysis
UOG Journal Club: January 2016
بنام خدا.
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the.
Antenatal Screening Rebecca Sykes.
Aneuploidy and NTD screening
DO NOT ORDER at any gestational age.
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
Genetic Testing Result Means. Before Genetic Testing  The result of genetic testing can be life changing.  It is important for patients and their families.
Non Invasive Prenatal Testing for Aneuploidy (NIPT)
غربالگری ناهنجاریهای جنین
Prenatal Screening for Genetic Conditions
Expert Perspectives on NIPT
guidance on antenatal screening
Following screening, genetic testing can occur during pregnancy for Down syndrome, Trisomy 18, and other conditions. Two major types of genetic testing.
Ultrasound in fetal screening ( Down syndrome,…)
NON – INVASIVE PRENATAL TESTING
Most provincial and territorial health insurance programs cover prenatal blood screening for chromosomal anomalies (Down syndrome and Trisomy 18) and neural.
Nuchal translucency screening uses ultrasound to screen for Down syndrome, other conditions caused by an extra chromosome (trisomy 13 and 18), and congenital.
Presentation transcript:

Vancouver Division of Family Practice and Perinatal Services BC Prenatal Genetic Screening Program Present: Prenatal Genetic Screening Langley Division of Family Practice Mar 1, 2016

Program Disclosure Nothing to disclose. Presenter Disclosure

AGENDA Prenatal Genetic Screening Tests Counselling Patients & video Workflow and Practice Tips Wrap Up & Evaluations Here is our plan for the evening. Speak about the additions that were brought up. Anything not mentioned here? Anything to emphasize? Resource Binder

Learning Objectives At the end of this workshop, the participants will: Know what tests to offer for screening for Down syndrome and the importance of timing. Be familiar with the technology of non-invasive prenatal testing (NIPT) using cell free fetal DNA in maternal blood. Know what screening options are available in the public system and what is available as self-pay Know how to use the patient decision aid and follow up counseling.

Screening for Aneuploidy Important for all ages ~40% of fetuses with trisomy 21 occur in women <35 years

SOGC – CCMG guideline on screening for Aneuploidy J Obstet Gynaecol Can 2011;33 (7):746-750 1. All pregnant women in Canada, regardless of age, should be offered through an informed counseling process, the option of a prenatal screening test for the most common clinically significant fetal aneuploidies in addition to a second trimester ultrasound for dating, assessment of fetal anatomy, and detection of multiples . (I-A)

What Are The Tests? SIPS IPS TEST METHOD WHEN WHAT QUAD FTS NIPT 1st Blood test 2nd Blood Test 9w to 13+6w 15w to 20+6w PAPPA AFP, HCG, UE3, and Inhibin A IPS 1st Blood Test and Nuchal Translucency US AFP ,HCG, UE3, and Inhibin A QUAD Blood test FTS Blood test and US: NT, nasal bones, Ductus Venosis flow, and fetal heart rate 11w-14w PAPPA, AFP, HCG NIPT 10w plus Cell free fetal DNA Nipt detection rate for t21 is 99%. Maternal blood sample. 10 days turn aroun. 2-4% give no result due to technical reasons. women choose NIPT as a first line test. Refer to Lifelabs in lower mainland Panoarama by life labs. Harmony test used by Womens Hospital, BCWH genetics will arrange testing for women eligeable for amniocentesis (still have to pay)

Who gets what? SIPS (two blood tests): Singleton pregnancies of women < 35 yrs. who present up to 13 weeks +6 days. IPS (NT + two blood tests): if woman seen up to 13 weeks + 6 days and: > 35 years Previous history of Trisomy IVF/ICSI HIV positive women All pregnancies of multiples

Who gets what? Quad: CVS or Amnio Singleton or twin pregnancies that present > 13 weeks 6 days CVS or Amnio Women age 40 or more with singletons or age 35 with multiples have option of CVS or amniocentesis without prior screening Women with a positive SIPS, IPS, NIPT

Prenatal Genetic Screening Private Pay Options First Trimester Screen (FTS) alternative to IPS or SIPS 11-14 weeks Ultrasound and one blood sample: T, nasal bone, fetal heart rate, Ductus Venosis flow, PAPPA-A/fbHCG Advantage? result same day as US; fewer false positives Available at PCRM Non Invasive Prenatal Test (NIPT) prior to amniocentesis 10+ weeks Fetal DNA in maternal blood Highly accurate screen to detect T21 and T18 Advantage?: result 10 days after blood draw. Fewest false pos. Does not screen for open neural tube defect Nipt detection rate for t21 is 99%. Maternal blood sample. 10 days turn aroun. 2-4% give no result due to technical reasons. women choose NIPT as a first line test. Refer to Lifelabs in lower mainland Panoarama by life labs. Harmony test used by Womens Hospital, BCWH genetics will arrange testing for women eligeable for amniocentesis (still have to pay)

Prenatal Genetic Screening Timing Chose test by woman’s GA and her characteristics Acronyms are defined on the Summary/checklist Women >35 qualify for IPS-- better because reduces false positives Women >30 in Northern Health, East Kootnay, Kootenay, Boundary eligeable for IPS at younger age Also: twins, prev T21,18,13,and IVF, ICSI eligible for IPS NOTE: IPS available for women: > 30 in Northern Health, Kootenays, Boundary; twins; previous trisomy; IVF and ICSI

Prenatal Genetic Screening Timing PSBC Resource cards summarize all tests for whom and when: Tests available & best times Tests for woman characteristics and time she presents for care

Ideal Timeline for SIPS and IPS SIPS part 1 any time before 13+6 SIPS part 2 at 15+2 10 days for results Only 64% have blood drawn this early- we could do better For pos SIPS offer NIPT 10 days for results For pos NIPT offer amnio 4-14 days for results

Non Invasive Prenatal Testing ~ 10% of DNA in maternal plasma is FETAL

Counting methodologies counted vs. expected HARMONY = Maternal DNA from chr. 21 = Fetal DNA from chr. 21 Unaffected pregnancy Pregnancy with Trisomy 21 ~ 10% of cfDNA in maternal blood is fetal (placental) The difference in the amount of DNA in an unaffected pregnancy vs an affected pregnancy is small: 21/20 = 1.05

SNPS method PANORAMA Explain SNPs

Comparison of Available Tests: Ariosa Harmony Natera Panorama Degree of validation 13 clinical studies >22,000 pregnancies with known outcomes 3 clinical studies 1,306 pregnancies with known outcomes. Measures fetal fraction YES Failure rate on 1st draw 3% 6-7% Twins NO Where C&W laboratory; JPOC Surrey Olive; Grace; PCRM; Gamma Dynamics Life Labs 17

Non Invasive Prenatal Testing (NIPT) What role should NIPT play in prenatal screening?

Position Statements: NIPT SOGC Position Screening 2013 Endorses NIPT in lieu of invasive testing for increased risk of trisomy Pre and post-test counselling re: false pos., false neg., and limitations Does not “replace” the accuracy and precision of invasive testing

NEW: Public Funding in BC for NIPT NIPT has been approved by the BC Ministry of Health effective immediately for women who meet one of the following criteria: Has received a Positive Screen result from IPS, SIPS, or Quad; OR Has had a previous trisomy 13, 18, 21 pregnancy; OR Has a risk of Down syndrome greater than 1 in 300 based on results of serum screening and ultrasound marker of aneuploidy Funding is available for NIPT analysis of Trisomy 21, 13, 18 and sex aneuploidy.

NIPT in lieu of invasive testing in high risk patients: “2nd tier test” Pre-screen counseling FP, MW, OB, GC SIPS / IPS / Quad Increased risk for aneuploidy (**) Genetic counselling Invasive testing* Amniocentesis CVS **Increased risk for trisomy Pos. screen Family hx US markers NIPT +ve NOTE: *Invasive testing still required for pos. NIPT *NIPT not offered for soft markers alone unless serum testing done *Fetal loss rate 0.5-1%

Where to access FUNDED NIPT Dynacare Harmony NIPT chosen to be the FUNDED NIPT provider for BC Hospital out-patient labs will be collecting for Harmony New PGSP / Dynacare NIPT Lab Req will be provided to you by the PBL each time you receive a patient’s positive screen result; OR For the other funded indications, refer patient to Med Gen. or fax information and form faxed back. Patient-specific authorization codes to be used for monitoring funding eligibility.

Important: NIPT can be false positive REASONS: Confined placental mosaicism: trisomy 18, trisomy 13 or 45,X line confined to the placenta Maternal mosaicism: low grade T21 mosaicism, low grade 45,X mosaicism Fetal demise in a twin pregnancy Maternal malignant cell line: multiple chrom abn. Sample error

Soft Markers on Ultrasound Several markers identified on 2nd trimester ultrasound are associated with increased risk of Down syndrome.

Which soft markers impact Down Syndrome risk? Significantly increased risk: Nuchal thickness ≥ 6mm Echogenic bowel (equal or greater than bone) Absent nasal bone (2nd T) Aberrant right subclavian artery Echogenic intracardiac focus (EICF) Pyelectasis 5mm-10mm Abnormal femur/foot ratio (≤0.9) *RISK CALCULATOR UNDER DEVELOPMENT Small impact on Down Syndrome risk:

Take home messages Provide informed consent - offer tests Remember some women choose no screening Be aware of your own biases and choices See women early to be able to do SIPS or IPS Order second SIPS early: close to 15+2 Quad screen at 14-20 weeks is an inferior test Offer private pay options NIPT does not test for open neural tube defect Positive NIPT is not diagnostic. Confirmatory test needed

Medical Genetics experts are only a phone call away! Medical Genetics Dept. at C&W T: 604-875-2157 Prenatal Biochemistry Screening Lab at C&W T: 604-875-2331

Vancouver Division of Family Practice and UBC Division of Continuing Professional Development Present: Prenatal Genetic Screening: Counseling Tips and Techniques

Things to Keep in Mind Local resources - What prenatal screening options are available in your area? Informed choice - Before ordering the test, discuss benefits, risks and limitations (screening vs. diagnosis) Autonomy - The patient should choose the option that is best for her (her family) Shared decision making

Essential Elements of Communication in Medical Encounters Open the discussion Gather Information/Understand the patient's perspective Share Information Share Decision-making Agree on Plan Provide Closure Ref: Essential Elements of communication in Medical Encounters: The Kalamazoo Consensus Statement Academic Medicine April 2001 - Volume 76 - Issue 4 - p 390–393

1. Open the Discussion Allow the patient to complete his or her opening statement Elicit the patient's full set of concerns Summarize what the visit entails- encourage Q Establish/maintain a personal connection “Is it ok to have this visit focus on genetic screening - are there any other pressing concerns?” What is the context re timeline? Decision needs to be made by ____ If a second appointment is needed and possible, let woman there is an opportunity for future discussion. Check if everyone who is part of the decision is here or can be included.

2. Gather Information Ask what the woman/partner understand “Do you know what Down Syndrome is? …NTD?” Use open-ended and closed-ended questions Actively listen and encourage Nonverbal (eye contact) Verbal (words of encouragement) Summarize and clarify Acknowledge her feelings, values, and ideas

2. Understand Woman’s Perspective Explore her context (family, culture, age) Explore beliefs and expectations about health and illness, knowing/not knowing Why might one get tested? Why would you want to know? What does she and her family think about this? How are decisions made in her family? Be aware of your own biases and values : cultural, ethical, emotional on this topic. Reflect on this for a minute. Do you have a strong preference for what you would do in her shoes? and… How does your family make decisions?

3. Share Information Use language the woman can understand Think about grade 6 reading level or ESL Check for understanding Pause and ask what they understand Reflect back what you are hearing from them Encourage questions

3. Share Information: Content All pregnant women have some risk of trisomy/NTD Specific risks of trisomy/NTD based on age Screening vs. diagnosis Pro’s and con’s of screening: reassurance, worry, true and false pos/neg Results given as a risk: what this means Types of tests to choose, advantages/disadvantages of each. Her options based on: Age, resources available, gest. age, ability/choice to pay private Timing and next steps such as diagnostic testing

4. Share Decision Making Encourage the patient to participate in decisions to the extent he or she desires, and provide time frame Describe options: No testing Screening with no further testing Screening with further testing Describe scenarios or elicit from her Ask which scenario/choice makes sense for her Check if she has enough information; if anyone else needs to be involved in decision

5. Agree on Plan Summarize and affirm the plan of action Next steps next visit further information offered/ needed? further discussion offered/needed? results plan for unexpected outcomes

6. Provide Closure Ask whether the woman has other issues or concerns Discuss follow-up

Information for Families and Patient Decision Aid PSBC Pamphlet: Its Your Choice Genetic Screening Prenatal Decision Aid  A decision to make Information to help Not doing the test Doing the test Discussion with your care- provider What matters most to you? *this is in your course binder

Video Demonstration https://www.dropbox.com/sh/917au874e4npmbh /AAAwoeZlwrzOdHBfL0rhfbkaa?dl=0#lh:null- Pegasus%20EN%20vFINAL%20CHOIX%20WEB.mp 4

Teaching Aid

Questions/Comments?